Duravyu™ Wet AMD Trials Receive Third Consecutive Positive Safety Nod, Boosting Confidence Ahead of Topline Data
summarizeSummary
EyePoint announced its third consecutive positive recommendation from the Data Safety Monitoring Committee (DSMC) for its Phase 3 wet AMD trials for Duravyu™. The DSMC recommended the trials continue without modifications, citing a continued favorable safety profile. This positive clinical update follows recent negative financial news for EyePoint, including a significant increase in net loss and a sharp drop in Q1 2026 revenue, but reinforces earlier news that the pivotal Phase 3 trials remained on track. A third consecutive positive DSMC recommendation is a strong de-risking event for Duravyu™, significantly boosting confidence in the drug's safety profile ahead of crucial mid-2026 topline data. This reduces the likelihood of trial halts due to safety concerns and is a material positive catalyst for the company's primary pipeline asset. Investors will now keenly await the mid-2026 topline data for the Phase 3 trials, as this will be the next major catalyst determining the drug's commercial viability.
At the time of this announcement, EYPT was trading at $13.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $5.30 to $19.11. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.